Core Viewpoint - Nathan's Famous, Inc. reported its financial results for the first fiscal quarter ended June 29, 2025, showing a mixed performance with revenue growth but declines in net income and operating income compared to the previous year [1][2]. Financial Performance - Total revenues increased to $46,998,000 from $44,767,000 in the same period last year, reflecting a growth of approximately 5.5% [2][9]. - Income from operations decreased to $12,791,000 from $13,745,000, a decline of about 6.9% [2][9]. - Adjusted EBITDA was reported at $13,531,000, down from $14,281,000, representing a decrease of approximately 5.2% [2][12]. - Net income fell to $8,928,000 compared to $9,277,000, a decrease of about 3.8% [2][9]. - Earnings per diluted share decreased to $2.16 from $2.27, a decline of approximately 4.8% [2][9]. Segment Performance - License royalties decreased to $12,381,000 from $12,921,000, a decline of about 4.2% [2][10]. - Sales in the Branded Product Program increased by $2,929,000 to $29,075,000, a growth of approximately 11.2% [2][10]. - Sales from Company-owned restaurants decreased to $3,986,000 from $4,199,000, a decline of about 5.1% [2][10]. - Franchise restaurant sales increased by $791,000 to $18,444,000, a growth of approximately 4.5% [2][10]. Dividend Information - The Company paid a regular cash dividend of $0.50 per share on July 1, 2025, and declared a second quarterly cash dividend of $0.50 per share effective August 8, 2025, payable on September 5, 2025 [2][5]. Non-GAAP Financial Measures - The Company disclosed EBITDA and Adjusted EBITDA as non-GAAP financial measures to provide investors with insights into its operating performance and underlying business trends [3][4]. - EBITDA for the first quarter was $13,243,000, down from $14,093,000, while Adjusted EBITDA was $13,531,000 compared to $14,281,000 in the prior year [12].

Financial Data and Key Metrics Changes - The company reported total revenue of $87.7 million for Q2 2025, representing a 0.3% increase compared to Q2 2024, marking the first quarterly year-over-year revenue increase in eight quarters [32] - Adjusted EBITDA for Q2 2025 was $48.1 million, a decrease of 2.1% from Q2 2024, primarily due to planned headcount increases [32] - Adjusted net income for Q2 2025 was $28.4 million, up 3.2% from the prior year, driven by lower interest expenses and depreciation [33] - Free cash flow increased by 29% to $20.3 million compared to Q2 2024, attributed to effective management of receivables and lower interest expenses [11][33] Business Line Data and Key Metrics Changes - Corporate revenue reached a record $55.3 million in Q2 2025, a 6.9% increase from $51.7 million in Q2 2024, marking the highest growth in the past ten quarters [14][27] - SOHO revenue was $32.4 million, reflecting a planned decrease of 9.4% from $35.8 million in the prior year [22][29] - The corporate customer base grew to approximately 63,000, an 11% increase year-over-year, with a trailing twelve months revenue retention rate of 102% [16][27] Market Data and Key Metrics Changes - The company noted strong performance in the healthcare vertical, which is becoming a larger portion of total corporate revenue [15] - The public sector pipeline remains robust, with ongoing discussions and progress in the VA rollout [19][20] Company Strategy and Development Direction - The company aims to pursue customer acquisitions primarily in the healthcare space and drive revenue growth exceeding 6.25% for the year [7] - A focus on optimizing profitability in the SOHO channel while managing advertising investments is emphasized [22][24] - The company is studying the impact of the One Big Beautiful Bill Act, particularly regarding anticipated cuts to Medicaid and Medicare, and believes it is well-positioned to assist providers in reducing costs [12][21] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in achieving double-digit growth for the corporate business channel, supported by a strong sales pipeline [15] - The company is not experiencing a slowdown in demand from healthcare providers, despite challenges faced by major hospital systems [44][45] - Management expects to maintain a retention rate above 100% and is actively working on programs to improve customer retention [50] Other Important Information - The company concluded a $225 million bank facility to retire 6% notes due in October 2026, consisting of a $150 million term loan and a $75 million revolver [8][35] - The company repurchased approximately $12 million of its common stock during the quarter at an attractive valuation [11][33] Q&A Session Summary Question: Thoughts on demand and pipeline amidst hospital system challenges - Management indicated that they are not experiencing a slowdown and have closed significant deals with large health systems recently [44][45] Question: Drivers behind improved revenue retention rate - Key drivers include large strategic accounts, improved service methodologies, and programs targeting churn in the SMB sector [48][50] Question: Length of sales cycle in the public sector and partnerships - Sales cycles vary significantly, with smaller deals closing quickly while larger government contracts may take years [52][53] - The partnership with Accenture is progressing well, enhancing the company's position in the public sector [54]

FiscalNote Holdings (NOTE) Q2 2025 Earnings Call August 07, 2025 05:00 PM ET Speaker0Good evening. My name is Bob Burrows, Investor Relations for FiscalNotes, and we are pleased you all could join us. The purpose of today's call is to discuss FiscalNotes' second quarter twenty twenty five financial results and guidance for both the full year and 2025. Joining me with prepared comments are Josh Resnick, CEO and President and John Slabaugh, CFO and Chief Investment Officer. Other members of the senior managem ...

Financial Data and Key Metrics Changes - Revenue for Q2 2025 reached a record $30,800,000, up 136% from $13,000,000 in Q2 2024 [22] - Positive net income of $300,000 reported, compared to a net loss of $10,000,000 in the previous year, marking the first positive net income in Q2 [7][24] - Adjusted EBITDA for Q2 2025 was $10,800,000, compared to $200,000 in Q2 2024 [25] - Total cash and cash equivalents at the end of Q2 2025 were $17,000,000, down from $39,300,000 in Q2 2024 [27] Business Line Data and Key Metrics Changes - FMS contributed $400,000 in revenue during Q2 2025, with optimism for year-round revenue growth despite delays due to federal budgeting [11][12] - Revenue from ongoing operations more than doubled to $25,700,000 compared to $11,200,000 in Q2 2024 [22] Market Data and Key Metrics Changes - Year-to-date wildfires have been above average in count with approximately 40,000 fires, but below average in acreage burned at just over 3,000,000 acres [10] - The company secured two separate 120-day task orders for its Super Scoopers, indicating strong adoption of its firefighting assets [8][9] Company Strategy and Development Direction - The company is focused on year-round demand and maximizing fleet utilization, with a strategy to enhance operational effectiveness through new technologies [10][12] - Plans to develop a new water scooping firefighting aircraft, the FF72, with the first delivery scheduled for 2029 [13] - The company is pursuing exclusive use contracts with states to provide firefighting assets, anticipating increased demand due to year-round wildfire threats [20] Management's Comments on Operating Environment and Future Outlook - Management highlighted the significance of the President's executive order to restructure the national wildland firefighting system, which is expected to enhance efficiency and effectiveness in wildfire management [17][18] - The company is optimistic about future growth driven by federal and state initiatives aimed at improving wildfire response and management [20][30] Other Important Information - The company plans to use proceeds from a sale-leaseback transaction of its Bozeman campus facilities to repay outstanding debt, which will lower ongoing interest expenses [27] - Guidance for 2025 anticipates adjusted EBITDA of $42,000,000 to $48,000,000 on revenue of $105,000,000 to $111,000,000, with expectations for continued improvement in cash flow [28] Q&A Session Summary Question: What is the outlook for the company's growth? - The company is trending towards the higher end of its annual guidance due to increased adoption of its aircraft and record task orders [30] Question: Are there any updates on the Spanish Super Scoopers? - The company plans to revisit guidance after reporting third-quarter results, which are expected to represent the bulk of revenue and adjusted EBITDA for the year [28]

CALGARY, Alberta, Aug. 07, 2025 (GLOBE NEWSWIRE) -- Maxim Power Corp. ("MAXIM" or the "Corporation") (TSX: MXG) announced today the release of financial and operating results for the second quarter ended June 30, 2025. The unaudited condensed consolidated interim financial statements, accompanying notes and Management’s Discussion and Analysis (“MD&A”) will be available on SEDAR+ and on MAXIM's website on August 7, 2025. All figures reported herein are Canadian dollars unless otherwise stated. FINANCIAL HIG ...

Core Insights - VitalHub Corp. reported a significant increase in Annual Recurring Revenue (ARR), which rose by 55% year-over-year to $79.6 million [1][10] - Total revenue for the second quarter of 2025 increased by 47% year-over-year to $23.9 million [1][8] - Adjusted EBITDA also saw a substantial rise, up 50% year-over-year to $6.3 million [1][8] Financial Performance - For the three months ended June 30, 2025, revenue was $23,857,548, compared to $16,237,605 in the same period last year, marking a 47% increase [7][8] - For the six months ended June 30, 2025, total revenue reached $45,532,514, up 45% from $31,494,396 in the prior year [7][8] - Gross profit as a percentage of revenue remained stable at 81% for both Q2 2025 and Q2 2024 [8][9] Growth Drivers - The ARR growth of $28,305,511 or 55% from $51,283,570 at June 30, 2024, was driven by organic growth of $7,329,129 (14%) and acquisition growth of $18,470,000 (36%) [8][10] - The company closed significant acquisitions, including Novari Health and Induction, which are expected to enhance its product offerings in electronic referral and patient engagement solutions [3][8] Cash Position - As of June 30, 2025, VitalHub had a cash balance of $94,008,665, an increase from $56,574,904 at the end of 2024 [10][11] - The company arranged a $15 million loan for acquisition financing, which was fully repaid after the quarter-end [8][10] Strategic Outlook - VitalHub aims to continue its international expansion, supported by a robust cash position and a strong ARR [3][11] - The company is focused on integrating its recent acquisitions to build a consolidated financial profile [3][11]

Financial Data and Key Metrics Changes - For Q2 2025, total net sales were $193.5 million, a 22% decline compared to the same quarter last year, primarily due to disruptions from U.S. tariff policies [8][9] - Gross profit was $62 million, resulting in a gross margin of 32.1%, down from 42% in Q2 of the previous year [9][10] - Adjusted net loss was $26.7 million or $0.48 per share, compared to adjusted net income of $5.6 million or $0.10 per diluted share in the prior year [10] - Negative adjusted EBITDA was $16.5 million, compared to adjusted EBITDA of $27.9 million in the same quarter last year [10][11] Business Line Data and Key Metrics Changes - Direct-to-consumer sales comprised 21% of gross sales, down from 23% in the same quarter last year [9] - The company experienced a significant decline in minimum guaranteed royalties due to sales disruptions and increased tariffs [10] Market Data and Key Metrics Changes - In the U.S. market, POS sales reported by larger wholesale customers were down just 5%, indicating resilience compared to the decline in year-over-year sell-in [13] - International business, representing over one-third of sales, saw 18% POS sales growth in the first half of the year and 28% growth in Q2 [13] Company Strategy and Development Direction - The company is focused on accelerating organic growth initiatives and exploring financial and strategic options, including a search for a new CEO [6][18] - A tariff mitigation plan has been implemented, including price increases in the U.S. market and shifting production out of China [14][15] - The company aims to fully offset the financial impact of incremental tariffs within the current year, with estimated costs reduced from $45 million to $40 million [14] Management's Comments on Operating Environment and Future Outlook - Management acknowledged the challenges posed by U.S. trade policies but expressed confidence in a robust plan for improved financial performance in the second half of the year [7][12] - The company expects second half net sales to be down in the high single digits compared to 2024, with adjusted EBITDA margins projected in the mid to high single digits range [12][33] Other Important Information - The company executed an amendment to its credit facilities, providing waivers for financial covenants, which offers additional flexibility during this period [15] - The company is focused on refinancing its debt due in September 2026 and has engaged advisors for this process [16] Q&A Session Summary Question: Adjusted EBITDA and SG&A items - Management noted that almost five points of margin decline year-over-year was attributed to the tariffs announcement, impacting adjusted EBITDA [22][23] Question: Resumption of orders - Management confirmed that orders paused in Q2 have resumed, with good visibility on Q3 order patterns [25][26] Question: Customer reaction to price increases - Early customer reactions to price increases have shown no negative impact on unit volumes, with continued strong sell-through [30][31] Question: Guidance on adjusted EBITDA margins - Adjusted EBITDA margins of mid to high single digits are expected for the second half of the year, with improvement from Q3 to Q4 [33] Question: Cash flow and liquidity - Management acknowledged liquidity challenges but emphasized the flexibility provided by the recent credit agreement amendments and the ATM filing [35][36]

Financial Overview - FTAI Infrastructure reported a net loss attributable to stockholders of $79.816 million for Q2 2025, compared to a loss of $54.350 million in Q2 2024 [2][24] - The basic and diluted loss per share for common stock was $0.73 for Q2 2025, compared to a loss of $0.52 in the same quarter of the previous year [2][24] - Adjusted EBITDA for Q2 2025 was $45.916 million, an increase from $34.256 million in Q2 2024 [2][24] Dividend Declaration - The Board of Directors declared a cash dividend of $0.03 per share for the quarter ended June 30, 2025, payable on September 8, 2025 [3] Business Highlights - The company agreed to acquire the Wheeling & Lake Erie Railway for $1.05 billion [9] - Plans to refinance existing 10.50% senior notes and Series A preferred stock upon closing of the acquisition [9] - Closed financing of $300 million of tax-exempt debt at Repauno with average coupons of 6.50%, with construction of phase 2 infrastructure fully underway [9] Key Performance Measures - Adjusted EBITDA is utilized as the key performance measure by the Chief Operating Decision Maker, providing insights into operational performance and resource allocation [21][22] - The reconciliation of net loss attributable to stockholders to Adjusted EBITDA for Q2 2025 indicates significant adjustments for various expenses, including interest and depreciation [23][24] Financial Position - Total assets as of June 30, 2025, were $4.407 billion, up from $2.374 billion as of December 31, 2024 [16][17] - Current assets increased to $539.045 million from $219.851 million year-over-year [16] - Total liabilities rose to $3.631 billion from $1.918 billion as of December 31, 2024 [17] Cash Flow Analysis - Net cash used in operating activities for the six months ended June 30, 2025, was $90.872 million, compared to $21.470 million in the same period of 2024 [19] - Cash flows from investing activities showed a net cash provided of $78.359 million, contrasting with a net cash used of $52.652 million in the previous year [19] - Net cash provided by financing activities was $313.480 million, up from $173.108 million in the same period of 2024 [19]

Core Insights - Tucows Inc. reported a 10.1% increase in consolidated net revenue for Q2 2025, reaching $98.5 million compared to $89.4 million in Q2 2024, driven by strong performance across all business segments [3][8] - The company achieved a 6.2% increase in gross profit, totaling $22.1 million, attributed to margin gains from Wavelo and Tucows Domains, despite a decrease in gross margin from Ting due to a one-time lease adjustment [4][8] - Adjusted EBITDA grew by 37% to $12.6 million, reflecting improved operational efficiency and revenue growth across all segments [6][8] Financial Performance - Net loss for Q2 2025 decreased to $15.6 million, or $1.41 per share, compared to a net loss of $18.6 million, or $1.70 per share, in Q2 2024, indicating improved operational efficiency [5][8] - Adjusted net loss for Q2 2025 was $16.3 million, or $1.47 per share, compared to an adjusted net loss of $17.8 million, or $1.63 per share, in Q2 2024 [5][8] - Cash and cash equivalents at the end of Q2 2025 were $68.6 million, up from $55.0 million at the end of Q1 2025 and $52.2 million at the end of Q2 2024 [7][8] Business Segment Performance - Ting Internet Services generated revenue of $16.4 million, up from $14.6 million in Q2 2024, with gross profit decreasing due to a one-time lease expense [9][10] - Wavelo Platform Services reported revenue of $12.7 million, an increase from $10.5 million in Q2 2024, with gross profit also rising [10] - Tucows Domain Services achieved revenue of $67.6 million, compared to $62.4 million in Q2 2024, with gross profit increasing to $21.6 million [10]

Financial Performance - Q2 2025 - Total revenue for Q2 2025 increased by 7% year-over-year, reaching $103 million[20] - Clinical Solutions revenue increased significantly by 32% compared to Q2 2024[21] - Gross margin improved from 292% in Q2 2024 to 387% in Q2 2025[23] - Adjusted EBITDA improved from a loss of $26 million in Q2 2024 to a loss of $08 million in Q2 2025[26] - Free cash flow improved from a negative $30 million in Q2 2024 to a negative $23 million in Q2 2025[28] Revenue Breakdown - 2024 - Catalog products accounted for approximately 60% of total revenue in 2024[14, 15] - Custom products represented about 35% of total revenue in 2024, with biopharma contributing 70% of custom revenue and 25% of total revenue[14, 15] - Other revenue, including services and shipping, made up roughly 5% of total revenue in 2024[14, 15] Customer Migration and Spending - Customers purchasing GMP reagents spent 44 times more annually compared to catalog-only customers in 2024[17] - 58% of 2024 revenue came from custom and/or clinical accounts[17] - 27% of 2024 revenue was generated from Cell and Gene Therapy (CGT) customers[17] 2025 Outlook - The company estimates total revenue between $39 million and $42 million, representing a 7% year-over-year increase at the midpoint[41] - The company is targeting a free cash outflow of less than $12 million for 2025[41] - The company estimates an annualized revenue range of $50 million to $55 million to achieve Adjusted EBITDA break-even[41]